Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative therapies to treat a variety of diseases, including cancer and autoimmune disorders. The company specializes in applying its proprietary drug delivery technology to enhance the efficacy and safety of existing therapies, as well as creating new treatments from the ground up. Nektar collaborates with other pharmaceutical organizations to advance its research pipeline and aims to address unmet medical needs by delivering transformative medicines that improve patients' lives. Read More
The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in rezpegaldesleukin’s potential as a differentiated treatment for atopic dermatitis.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Nektar Therapeutics said its mid-stage trial showed that patients who received Rezpegaldesleukin demonstrated improvement in eczema area and severity score compared to placebo at week 16.
Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Rezpegaldesleukin is being studied not only in atopic dermatitis but also in alopecia areata, with topline data from the second trial expected in December.
